European
stocks increased due to mergers and acquisitions plans in the pharma sector.
Pfizer has renewed its offer for AstraZeneca. A worth of the deal could be more
than $100 billion. European stock markets remained unimpressed by the new
sanctions on Russia.
But investors
still monitor closely tensions between Russia and Ukraine.
AstraZeneca
shares were up 14% because of the renewed offer of Pfizer.
Bayer AG
shares jumped 3.3% caused by the better-than-expected first quarter earnings.
Siemens AG
shares declined 2.7% after announcing the plan to buy Alstom. The Siemens’ plan
is an asset swap. Siemens wants to acquire Alstom’s power and grid business in
exchange for its transport assets and some cash. Alstom shares are suspended
until Wednesday.
Indexes on
the close:
Name Price Change Change %
FTSE
100 6,700.16 +14.47 +0.22%
DAX 9,446.36 +44.81 +0.48%
CAC 40 4,460.53 +16.90 +0.38%
© 2000-2026. All rights reserved.
This site is managed by Teletrade D.J. LLC 2351 LLC 2022 (Euro House, Richmond Hill Road, Kingstown, VC0100, St. Vincent and the Grenadines).
The information on this website is for informational purposes only and does not constitute any investment advice.
The company does not serve or provide services to customers who are residents of the US, Canada, Iran, The Democratic People's Republic of Korea, Yemen and FATF blacklisted countries.
Making transactions on financial markets with marginal financial instruments opens up wide possibilities and allows investors who are willing to take risks to earn high profits, carrying a potentially high risk of losses at the same time. Therefore you should responsibly approach the issue of choosing the appropriate investment strategy, taking the available resources into account, before starting trading.
Use of the information: full or partial use of materials from this website must always be referenced to TeleTrade as the source of information. Use of the materials on the Internet must be accompanied by a hyperlink to teletrade.org. Automatic import of materials and information from this website is prohibited.
Please contact our PR department if you have any questions or need assistance at pr@teletrade.global.